Why do we need a systematic review of pneumococcal conjugate vaccine dosing schedules?
- PMID: 24336052
- PMCID: PMC3940377
- DOI: 10.1097/INF.0000000000000075
Why do we need a systematic review of pneumococcal conjugate vaccine dosing schedules?
Conflict of interest statement
D.G.’s laboratory performs contract and or collaborative research for/with Pfizer, GlaxoSmithKline, Merck, Novartis and Sanofi Pasteur. D.G. has received travel or honorarium support for participation in external expert committees for Merck, Sanofi Pasteur, Pfizer and GlaxoSmithKline. K.O.B. received grant support from Pfizer, GlaxoSmithKline and has received travel or honorarium support for participation in external expert committees for Merck, Aventis-pasteur and GlaxoSmithKline. The authors have no other funding or conflicts of interest to disclose.
References
-
- O’Brien KL, Wolfson LJ, Watt JP, et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902. - PubMed
-
- Jayakumar M. Global burden of neonatal invasive pneumococcal disease: a systematic review and meta-analysis. PhD Dissertation, Johns Hopkins Bloomberg School of Public Health; 2011.
-
- Garcia CR, Johnson HL, Summers A, et al. Igaçu Falls, Brazil: March 11–15, 2012. Pneumococcal disease in older children and adults globally: results from the AGEDD project. 8th International Symposium on Pneumococci and Pneumococcal Disease;
-
- World Health Organization. Pneumococcal conjugate vaccine for childhood immunization—WHO position paper. Wkly Epidemiol Rec. 2007;82:93–104. - PubMed
-
- IVAC, Johns Hopkins Bloomberg School of Public Health. Vaccine information management system (VIMS) global vaccine introduction report. December, 2012. Available at: http://www.jhsph.edu/ivac/vims.html. Accessed May 20, 2013.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
